Generated by AI
Embecta Corp. is a medical device company focused on products and services that support diabetes management. Embecta Corp. offers a portfolio of pen needles, syringes, safety injection devices, and digital applications designed to help people living with diabetes use insulin and other injectable therapies. The company serves healthcare supply chains through wholesalers and distributors, with products reaching retail and institutional channels in the United States and international markets. Its offerings are used in routine diabetes care and medication delivery, making the company a specialized participant in the broader diabetes care market. Embecta Corp. is headquartered in Parsippany, New Jersey, and operates as a standalone healthcare company centered on essential injection and support solutions for people with diabetes.
Website300 Kimball Drive
Parsippany, NJ, 07054
United States
The latest articles about EMBC.
If you had paused on Embecta in late 2025, wondering whether steady diabetes-device cash flows and analyst price targets justified a position, the past year has delivered a harsh answer. Investors who held Embecta over the past year are down 53.6%, including dividends. With lawsuits now alleging misleading guidance and weak pen needle demand, the real question is which assumptions about earnings visibility and product resilience were already sitting in plain sight back on 6 November...
If you had backed Embecta on 19 October 2025 and simply held on, the experience would have been brutal. Holding Embecta over the past year would have meant a 54.5% loss, including dividends. At the start, bullish and bearish analysts were arguing over modest revenue shrinkage, margin expansion into the mid teens, and a future P/E between 7.4x and 4.7x. So what did that original investment case miss about pen needle reliance, GLP-1 partnerships and margin durability? The move put Embecta in...
Tipranks Press Release.
Summary of Aug 13's posts. Generated by AI.
Summary of May 7's posts. Generated by AI.
Summary of May 9's posts. Generated by AI.
No summary yet.
Summary of Aug 7's posts. Generated by AI.
Investors talking about EMBC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.